LH — Labcorp Holdings Inc.
Is LH overbought or oversold? Here is the current MarketMoodz read.
Labcorp Holdings Inc. (LH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $372.46. The rating moved from Neutral to Overbought on November 6, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$372.46
- Last changeMoved from Neutral to Overbought on November 6, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all overbought Healthcare stocks →
AI analysis
Labcorp combines stable diagnostic testing revenue with higher-growth drug development services, giving it diversified cash flow and exposure to secular trends in specialty testing and outsourcing. Defensive sector positioning and scale advantages support near-term stability, while margin expansion and selective M&A could drive upside. Key uncertainties include reimbursement pressure, competitive dynamics with other large lab providers, and sensitivity to biopharma R&D cycles. Short-term market tone is cautious risk-on, which favors large-cap healthcare names; catalysts include further uptake of specialty molecular tests and stronger-than-expected biopharma service demand.
Key factors
- Diversified revenue mix across diagnostics (steady recurring testing volumes) and drug development services (higher-margin, biopharma outsourcing demand).
- Defensive healthcare positioning supports relative stability in risk-off windows and attracts ETF flows into large-cap healthcare.
- Growing secular demand for specialty and molecular testing which can command premium pricing and higher margins over time.
- Operational scale and customer relationships (hospitals, physician groups, biopharma clients) create competitive advantages versus smaller lab operators.
- Potential M&A and consolidation tailwinds in diagnostics and lab services that could expand margins and market share.
- Strong free-cash-flow generation historically supports reinvestment, share repurchases or bolt-on acquisitions (subject to confirmation from filings).
Risks
- Reimbursement pressure from Medicare/private payors leading to margin compression or lower revenue per test.
- Volume normalization or declines post-pandemic for routine testing categories and infectious-disease panels.
- Intense competition from Quest Diagnostics and regional/local labs, putting pressure on pricing and client retention.
- Exposure to biopharma R&D cyclicality—slower drug development spending could reduce demand for CRO/Lab services.
- Regulatory and policy risk (reimbursements, lab regulations) and broader political scrutiny of healthcare sector consolidation.
- Integration risk from acquisitions and execution risk on margin-improvement programs.
See today's live rating, score and targets
Members see the live hourly rating for LH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.